Plasma cardiac troponin T as a marker of skeletal muscle involvement in amyotrophic lateral sclerosis

Clicks: 20
ID: 329555
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #98 of 196 articles by views in Brain communications

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 196 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Plasma cardiac troponin T (cTnT) is widely used as a marker of myocardial injury, yet recent studies suggest elevations in amyotrophic lateral sclerosis (ALS). Whether these elevations reflect disease-associated skeletal muscle remodelling remains unresolved. In this translational study, we analysed longitudinal plasma cTnT in a large clinical cohort comprising 496 patients with ALS and 84 with benign fasciculation syndrome (BFS). To investigate the biological origin of circulating cTnT, we examined publicly available skeletal muscle transcriptomes from patients with ALS (n=28) and healthy controls (n=17), and quantified troponin isoform expression in skeletal muscle from SOD1G93A mice and wild-type littermates. Plasma cTnT was significantly higher in ALS than in BFS (median 18 vs. 6 ng/L, p=3.6×10−27), with 57% of patients with ALS exceeding the cardiologic threshold of 15 ng/L. Diagnostic performance was high (area under the curve [AUC] 0.87), with excellent specificity (94%). Longitudinal modelling revealed a progressive increase in cTnT in ALS whereas levels remained stable in BFS. Skeletal muscle transcriptomics demonstrated robust upregulation of TNNT2, encoding cardiac troponin T, in ALS muscle, while other troponin isoforms were unchanged. In SOD1G93A mice, severely affected gastrocnemius muscle exhibited isoform-specific remodelling, including 20-fold upregulation of Tnnt2 and slow-fibre troponins, alongside downregulation of fast skeletal isoforms. Across clinical, transcriptomic, and experimental data, elevated plasma cTnT in ALS is best explained by disease-associated skeletal muscle remodelling rather than cardiomyocyte injury. Plasma cTnT emerges as a dynamic and accessible biomarker in ALS capturing muscle involvement. Prospective incorporation of cTnT into clinical trials and evaluation across broader neuromuscular differentials are warranted.
Reference Key
openalex_W7214069838 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Linn Öijerstedt, Jianing Lin, Aditya Singh, Solmaz Yazdani, Annamari M Saarinen, Ulf Kläppe, Alexander Juto, Sanharib Chamoun, Sofia Imrell, Fang Fang, Sebastian A. Lewandowski, Caroline Ingre
Are you one of these authors? Claim your profile
Journal Brain communications
Year 2026
DOI
10.1093/braincomms/fcag358
URL
https://doi.org/10.1093/braincomms/fcag358
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.